Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed)
ID: 343053Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/343053

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-223.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed)." This initiative aims to support mechanistic studies on host cell death pathways and immune responses related to Mycobacterium tuberculosis (Mtb) and Mtb/HIV co-infection, with the goal of identifying immune targets for the development of host-directed therapies. The research is crucial for enhancing treatment outcomes and advancing scientific knowledge in combating Mtb and associated infections. Applications are due by December 7, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-223.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-22-223-Full-Announcement.html
    PAR-22-223.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and its National Institute of Allergy and Infectious Diseases (NIAID), has issued a Funding Opportunity Announcement (FOA) focused on mechanistic studies of host cell death pathways in relation to Mycobacterium tuberculosis (Mtb) and Mtb/HIV co-infection. The goal is to identify immune targets for host-directed therapies to enhance treatment outcomes. The announcement encourages cross-disciplinary research and emphasizes the importance of understanding how Mtb interacts with cell death mechanisms, which includes identifying potential cellular targets for new therapies. Funding details stipulate that applications are accepted until December 08, 2024, budgets need to reflect project needs, and proposals cannot involve clinical trials. Eligible applicants encompass various institutions, including higher education entities and nonprofits, with an encouragement for diverse participation. Review criteria will revolve around the significance of the proposed research, investigator qualifications, innovation, and the robustness of the approach. The initiative not only aims to advance scientific knowledge but also hopes to provide substantial benefits in combating Mtb and associated infections through enhanced therapeutic strategies.
    Similar Opportunities
    Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders," aimed at supporting research into the mechanisms linking autophagy, HIV infection, and substance use disorders. This initiative seeks innovative proposals that explore the interactions between neuroinflammatory responses, neurotransmission, and autophagy, with the goal of identifying therapeutic pathways for intervention. Eligible organizations can apply for up to four grants totaling $2 million, with applications due by November 15, 2024. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-009.html.
    Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS)," aimed at supporting multidisciplinary research teams investigating HIV pathogenesis and its associated comorbidities. The initiative seeks to foster collaboration among experts in HIV science, pathobiology, metabolism, and related fields to explore critical health issues such as gastrointestinal health, liver diseases, kidney function, and obesity in the context of HIV. With a total funding allocation of $2 million for 2-3 anticipated awards, applicants can request up to $500,000 per year for a maximum of five years, with proposals due by November 21, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details.
    Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 Exploratory/Developmental Research Grant focused on the interplay of autophagy-regulated cell death and HIV pathogenesis in the context of substance use disorders. This funding opportunity aims to enhance understanding of the mechanisms of autophagy and their implications for managing HIV infection and related health issues among individuals with substance use disorders, encouraging innovative mechanistic studies and preclinical research. The grant offers a funding ceiling of $275,000 for a two-year project period, with applications due by November 14, 2024, and awards expected to be announced in early 2025. Interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)," aimed at supporting research on the long-term cardiopulmonary effects following tuberculosis (TB) treatment in both adults and children, particularly focusing on individuals with and without HIV. This initiative encourages innovative epidemiological and observational studies to better characterize post-TB lung disease (PTLD) and its associated health impacts, utilizing existing cohorts of TB participants. Interested applicants, including higher education institutions, non-profits, and government entities, must adhere to specific guidelines for submission through the NIH ASSIST system, with applications accepted until May 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Halting Tuberculosis (TB) Transmission (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Halting Tuberculosis (TB) Transmission," aimed at understanding and addressing the critical drivers of TB transmission in high-burden settings. The initiative seeks to develop effective measurement methods and assess potential low-cost interventions to prevent TB transmission, with a particular focus on the role of asymptomatic TB and leveraging insights from COVID-19 research. A total of $6 million is anticipated for FY 2025 to fund 4-5 awards, with each application budget capped at $750,000 per year over a maximum project period of 5 years. Eligible applicants include a diverse range of organizations, and interested parties can find more information and submission details at the provided NIH link, with applications due by December 4, 2024.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research to develop molecules that target HIV proteins or RNA for degradation. The initiative encourages applications focusing on novel therapeutic methods rather than traditional drug discovery approaches, with a total funding amount of $1.2 million anticipated for one to two awards in fiscal year 2025. This opportunity is particularly significant as it seeks to advance research that could overcome existing limitations in HIV treatment methodologies, fostering diverse applicant eligibility from various institutions and organizations, including historically underrepresented groups. Interested applicants must submit their proposals by December 5, 2024, and can find additional information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Cellular Models of HIV Pathogenesis within NIDDK Mission Areas (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has announced a funding opportunity for research focused on developing cellular models of HIV pathogenesis. This initiative aims to enhance understanding of HIV interactions with human tissues by utilizing innovative three-dimensional models, such as organoids and microphysiological systems, to investigate mechanisms of viral persistence and associated co-occurring conditions. The funding opportunity allows for a budget of up to $500,000 annually, with a total commitment of $3 million for the fiscal year 2026, and applications are due by March 20, 2025. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-021.html.
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)." This initiative aims to identify innovative cure strategies that can be implemented at the onset of combination antiretroviral therapy (cART) or upon restarting cART after an analytical treatment interruption, with the ultimate goal of achieving sustained treatment-free remission. The NIH encourages multidisciplinary research approaches that enhance understanding of HIV dynamics and improve strategies for sustained remission, while excluding clinical trials. Interested applicants, including a diverse range of institutions such as historically black colleges, tribal governments, and community-based organizations, must submit their proposals by September 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-297.html.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.